Compare Sony Group Corp (SONY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Tango Therapeutics Inc. — how do they compare? Sony Group Corp trades at $24.5 (market cap $140.46B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Sony Group Corp is far larger — about 37.5× Tango Therapeutics Inc.'s market cap, and Sony Group Corp pays a 0.65% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and Tango Therapeutics Inc. for 0 Days on average.
| SONY | TNGX | |
|---|---|---|
Market Cap | $140.46B | $3.75B |
Volume | 5,764,125 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $30.26 | $32.90 |
52-Week Low | $19.32 | $7.50 |
Typical Hold Time | 96 Days | 0 Days |
Enterprise Value | $138.37B | $2.77B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $24.36, up 0.41% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats, though Q1 2026 missed expectations. Revenue remains stable around $12.96T with improving operating cash flow of $2.32T. Analyst sentiment is strongly positive with 11 buy ratings and no sell recommendations, while recent news highlights Sony's content moat and AI litigation developments.
Sony presents a compelling investment case with solid fundamentals and strong analyst support, though negative net income margin and ROE raise concerns. The stock's valuation appears reasonable with P/E of 20.65 and EV/EBITDA of 8.05. Key risks include content competition and AI-related legal challenges, while opportunities lie in Sony's entertainment ecosystem and strategic expansion.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
